SAN DIEGO, Calif., March 14, 2017 /PRNewswire-USNewswire/ -- Patients who take selective serotonin reuptake inhibitors (SSRIs), commonly prescribed medications used to treat anxiety and depression, may experience a reduced risk of revision surgery following total hip (THR) or total knee replacement (TKR), according to new research presented today at the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).
Depression, which is common in patients undergoing THR and TKR, has long been associated with poor patient-reported orthopaedic outcomes, higher complication rates, longer hospital stays and increased costs.
In a first-of-its-kind study, researchers reviewed the records of more than 20,000 THR and TKR patients age 18 and older from 2002 through 2009, including patient and surgery characteristics and outcomes (dates of care, types of complications, revisions and mortality). Patient medication records, beginning at admission and ending at discharge, determined SSRI use. Among the results:
While the use of SSRIs before and after surgery has been associated with some side effects, including bleeding, the study authors conclude that the continuation of SSRIs for THR and TKR patients does not have detrimental effects on the risk of revision and related complications.
"Depression and psychiatric comorbidity and antidepressant medications are rarely considered when evaluating perioperative risk factors among hip and knee replacement candidates," said Dr. Berry. "Studies such as this raise awareness to better recognize and manage comorbidities and chronic medications in these patients."
Study abstract
View the 2017 AAOS Annual Meeting Disclosure Statements
The American Academy of Orthopaedic SurgeonsWith more than 39,000 members, the American Academy of Orthopaedic Surgeons (AAOS) is the world's largest association of musculoskeletal specialists. The AAOS provides education programs for orthopaedic surgeons and allied health professionals, champions and advances the highest musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments, and related issues.
Visit AAOS at:Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.Facebook.com/AAOS1 Twitter.com/AAOS1
Advertisement
Depression, which is common in patients undergoing THR and TKR, has long been associated with poor patient-reported orthopaedic outcomes, higher complication rates, longer hospital stays and increased costs.
Advertisement
In a first-of-its-kind study, researchers reviewed the records of more than 20,000 THR and TKR patients age 18 and older from 2002 through 2009, including patient and surgery characteristics and outcomes (dates of care, types of complications, revisions and mortality). Patient medication records, beginning at admission and ending at discharge, determined SSRI use. Among the results:
- A diagnosis of depression was present in 1,290 (6.4 percent) of patients, and SSRIs were administered in 1,563 (7.8 percent) of patients.
- Depression was associated with a doubling of joint infection risk, overall long-term risk of revisions, and revisions for aseptic loosening (a failure of the bond between the bone and the implant).
- SSRI-users appeared to have a similar rate of joint infections compared with non SSRI users; however, patients who received perioperative SSRIs experienced an almost 60% lower rate of revision surgery, including revisions for aseptic loosening.
While the use of SSRIs before and after surgery has been associated with some side effects, including bleeding, the study authors conclude that the continuation of SSRIs for THR and TKR patients does not have detrimental effects on the risk of revision and related complications.
"Depression and psychiatric comorbidity and antidepressant medications are rarely considered when evaluating perioperative risk factors among hip and knee replacement candidates," said Dr. Berry. "Studies such as this raise awareness to better recognize and manage comorbidities and chronic medications in these patients."
Study abstract
View the 2017 AAOS Annual Meeting Disclosure Statements
The American Academy of Orthopaedic SurgeonsWith more than 39,000 members, the American Academy of Orthopaedic Surgeons (AAOS) is the world's largest association of musculoskeletal specialists. The AAOS provides education programs for orthopaedic surgeons and allied health professionals, champions and advances the highest musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments, and related issues.
Visit AAOS at:Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.Facebook.com/AAOS1 Twitter.com/AAOS1
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/for-select-patients-taking-medication-to-treat-anxiety-depression-before-and-after-hip-or-knee-replacement-surgery-reduces-revision-risk-300422619.html
SOURCE American Academy of Orthopaedic Surgeons